Synergistic effect of iontophoresis and a series of fatty acids on LHRH permeability through porcine skin

被引:33
作者
Bhatia, KS [1 ]
Singh, J [1 ]
机构
[1] N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58105 USA
基金
美国国家科学基金会;
关键词
D O I
10.1021/js970301f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The effect of chemical penetration enhancers (e.g., fatty acids) in combination with iontophoresis was examined on the in vitro permeability of luteinizing hormone releasing hormone (LHRH) through porcine skin. Porcine epidermis was pretreated with either ethanol (EtOH) or 10% fatty acid/EtOH. The permeability coefficient of LHRH was significantly (p < 0.05) greater through ROH, lauric acid/EtOH, palmitic acid/EtOH, oleic acid/EtOH, linoleic acid/EtOH, and linolenic acid/EtOH treated epidermis than the control (untreated epidermis). lontophoresis further enhanced the permeability of LHRH (p < 0.05) through enhancer-pretreated epidermis in comparison with corresponding passive permeability. Among saturated fairy acids tested, 10% palmitic acid/iontophoresis showed the highest permeability coefficient [(59.52 +/- 2.40) x 10(-4) cm/h], which was approximately 16-fold higher than that of the control [(3.57 +/- 0.41) x 10(-4) cm/h]. Unsaturated cis-octadecenoic acids were more effective penetration enhancers when compared with octadecanoic acid. Among cis-octadecenoic acids in combination with EtOH, the greater iontophoretic permeability coefficient [(59.18 +/- 12.43) x 10(-4) cm/h] was obtained through linolenic acid treated epidermis, which was significantly greater (p < 0.05) than through saturated octadecanoic acid treated epidermis [(29.08 +/- 3.18) x 10(-4) cm/h]. Also, pretreatment of epidermis with 5% linolenic acid/propylene glycol (PG) resulted in greater Gt,< 0.05) iontophoretic flux ct LHRH in comparison to 5% linolenic acid/EtOH. Furthermore, increases in the degree of unsaturation in octadecenoic acids did not produce corresponding increases in the degree of enhancement. Reversibility studies revealed that the postrecovery passive flux of LHRH through 5% linolenic acid in combination with EtOH or PG/iontophoresis treated epidermis was significantly (p < 0.05) reduced than the prerecovery value but could not completely recover to the baseline flux (i.e., flux of LHRH through untreated epidermis).
引用
收藏
页码:462 / 469
页数:8
相关论文
共 60 条
[1]  
[Anonymous], 1996, PHARM PHARM COMMUN, DOI DOI 10.1111/J.2042-7158.1996.TB00610.X
[2]  
Aungst B, 1995, PERCUTANEOUS PENETRA, P277
[3]   CONTRIBUTIONS OF DRUG SOLUBILIZATION, PARTITIONING, BARRIER DISRUPTION, AND SOLVENT PERMEATION TO THE ENHANCEMENT OF SKIN PERMEATION OF VARIOUS COMPOUNDS WITH FATTY-ACIDS AND AMINES [J].
AUNGST, BJ ;
BLAKE, JA ;
HUSSAIN, MA .
PHARMACEUTICAL RESEARCH, 1990, 7 (07) :712-718
[4]   ENHANCEMENT OF NALOXONE PENETRATION THROUGH HUMAN-SKIN INVITRO USING FATTY-ACIDS, FATTY ALCOHOLS, SURFACTANTS, SULFOXIDES AND AMIDES [J].
AUNGST, BJ ;
ROGERS, NJ ;
SHEFTER, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 33 (1-3) :225-234
[5]   TRANSDERMAL PERMEATION OF VASOPRESSIN .2. INFLUENCE OF AZONE ON INVITRO AND INVIVO PERMEATION [J].
BANERJEE, PS ;
RITSCHEL, WA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 49 (03) :199-204
[6]  
BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6
[7]   EFFECT OF PENETRATION ENHANCERS ON THE PERMEATION OF MANNITOL, HYDROCORTISONE AND PROGESTERONE THROUGH HUMAN-SKIN [J].
BARRY, BW ;
BENNETT, SL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1987, 39 (07) :535-546
[8]   ENHANCED PERCUTANEOUS-ABSORPTION VIA IONTOPHORESIS .1. EVALUATION OF AN INVITRO SYSTEM AND TRANSPORT OF MODEL COMPOUNDS [J].
BELLANTONE, NH ;
RIM, S ;
FRANCOEUR, ML ;
RASADI, B .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 30 (01) :63-72
[9]  
BENNETT SL, 1984, J PHARM PHARMACOL, V37, P298
[10]   ETHANOL - WATER MUTUALLY ENHANCED TRANSDERMAL THERAPEUTIC SYSTEM .1. NITROGLYCERIN SOLUTION PROPERTIES AND MEMBRANE-TRANSPORT [J].
BERNER, B ;
OTTE, JH ;
MAZZENGA, GC ;
STEFFENS, RJ ;
EBERT, CD .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (04) :314-318